Hot Blue Chip Stocks To Own For 2019

They’ve each crafted massive consumer-facing businesses that, over the decades, have delivered awesome returns for long-term shareholders. However, both Procter & Gamble and Pepsi are struggling with market share losses today that have caused Wall Street to turn more pessimistic about their growth outlooks.

The good news is that this sour mood has pushed dividend yields to nearly 4% for these blue chip stocks. But which one might make the better investment today? Let’s take a closer look.

P&G vs. Pepsi

Company Market Cap Sales Growth Operating Profit Margin Dividend Yield
Procter & Gamble (NYSE:PG) $183 billion 2% 15.7% 3.9%
PepsiCo (NASDAQ:PEP) $137 billion 2% 16.5% 3.8%

Data sources: Company financial filings. Sales growth excludes acquisitions and divestments and is on a constant-currency basis for the past complete fiscal year.

Hot Blue Chip Stocks To Own For 2019: Antares Pharma, Inc.(ATRS)

Advisors’ Opinion:

  • [By Brian Orelli]

    Shares of Antares Pharma (NASDAQ:ATRS) were up 11.8% at 3:12 p.m. EDT on Monday after the company announced a deal with Pfizer (NYSE:PFE) to develop a combination drug-device rescue pen.

  • [By Max Byerly]

    Antares Pharma (NASDAQ:ATRS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday.

  • [By Ethan Ryder]

    Antares Pharma (NASDAQ:ATRS) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

  • [By Logan Wallace]

    BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

  • [By Shane Hupp]

    HC Wainwright set a $5.00 price objective on Antares Pharma (NASDAQ:ATRS) in a research report released on Friday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

  • [By ]

    Antares Pharma (Nasdaq: ATRS), the smallest company in the top five, is a specialty pharmaceutical company developing and manufacturing proprietary delivery technology methods (such as self-injection systems for its partner pharmaceutical and biotech companies). This company’s expected growth makes it potentially attractive in terms of valuation, although ATRS depends on its partner companies for much of its future potential.

Hot Blue Chip Stocks To Own For 2019: Abbott Laboratories(ABT)

Advisors’ Opinion:

  • [By Brian Feroldi, Keith Speights, and Sean Williams]

    Investors looking for growth should still like AbbVie despite its Rova-T challenges. Income-seeking investors have just as much to like. AbbVie’s dividend yield currently stands just a notch below 4%. The company has increased its dividend payout by a whopping 140% since it was spun off from parent Abbott Labs (NYSE:ABT) in 2013.

  • [By Stephan Byrd]

    Summit Securities Group LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 57,500 shares of the healthcare product maker’s stock, valued at approximately $3,507,000. Abbott Laboratories makes up about 0.5% of Summit Securities Group LLC’s investment portfolio, making the stock its 22nd largest position.

  • [By Stephan Byrd]

    Schwab Charles Investment Management Inc. reduced its position in Abbott Laboratories (NYSE:ABT) by 4.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,028,813 shares of the healthcare product maker’s stock after selling 298,676 shares during the period. Schwab Charles Investment Management Inc. owned 0.40% of Abbott Laboratories worth $428,688,000 at the end of the most recent quarter.

  • [By ]

    Drug companies Eli Lilly (LLY) gained about 2%, Pfizer (PFE) added 1.3%, Abbott Laboratories (ABT) rose 1.2% and Bristol-Myers Squibb (BMY) advanced by 1.4% after the president promised lower list prices, less costs for patients and more competition among the drug makers.

Hot Blue Chip Stocks To Own For 2019: Credit Suisse Asset Management Income Fund, Inc.(CIK)

Advisors’ Opinion:

  • [By Shane Hupp]

    Credit Suisse AM Inc Fund Inc. (NYSEAMERICAN:CIK) announced a monthly dividend on Wednesday, June 27th, Wall Street Journal reports. Investors of record on Wednesday, July 11th will be given a dividend of 0.0225 per share on Tuesday, July 17th. This represents a $0.27 annualized dividend and a yield of 8.57%. The ex-dividend date of this dividend is Tuesday, July 10th. This is an increase from Credit Suisse AM Inc Fund’s previous monthly dividend of $0.02.

Hot Blue Chip Stocks To Own For 2019: RXI Pharmaceuticals Corporation(RXII)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

    Get RXi Pharmaceuticals alerts:

    New Research Study on Connective Tissue Growth Factor Market 2018 to 2025 (morningoutlook.com) Hypoxia Inducible Factor 1 Alpha Market Pipeline Therapeutics H1, 2018 Product Description, Mechanism of Action … (exclusiveherald.com) Human Papillomavirus Associated Diseases Market Pipeline Therapeutics 2018 Drug Description, Target Finding, and … (thefreenewsman.com) Warts Market Therapeutic Pipeline H1, Drugs, Diagnostics, Vaccines and Preventive Technologies (newspublicist.com) Brokerages Anticipate RXi Pharmaceuticals Corp (RXII) to Post -$0.56 Earnings Per Share (americanbankingnews.com)

    Shares of RXi Pharmaceuticals traded down $0.01, hitting $2.24, on Tuesday, MarketBeat Ratings reports. 55,400 shares of the stock were exchanged, compared to its average volume of 275,015. The company has a market capitalization of $9.96 million, a price-to-earnings ratio of -0.53 and a beta of 1.15. RXi Pharmaceuticals has a one year low of $1.90 and a one year high of $7.70.

  • [By Lisa Levin] Gainers
    ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share.
    Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook.
    vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June.
    Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results.
    RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results.
    Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million.
    Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter.
    Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales.
    Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings.
    MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma.
    New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor.
    Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session.
    Himax Technologies, Inc. (NASDAQ: HIMX) shares rose
  • [By Lisa Levin] Gainers
    MoSys, Inc. (NASDAQ: MOSY) shares rose 44.7 percent to $2.20 in pre-market trading after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    The Trade Desk, Inc. (NASDAQ: TTD) rose 23.2 percent to $65.01 in pre-market trading after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    Immersion Corporation (NASDAQ: IMMR) rose 17 percent to $13.55 in pre-market trading after reporting upbeat Q1 results.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) rose 13.8 percent to $23.50 in pre-market trading after the company disclosed that the FDA Advisory Committee voted in favor of WAYLIVRA for the treatment of familial chylomicronemia syndrome.
    RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 9.4 percent to $2.45 in pre-market trading after the company disclosed a collaboration with Iovance Biotherapeutics.
    ViewRay, Inc. (NASDAQ: VRAY) rose 13.7 percent to $8.80 in pre-market trading after reporting upbeat quarterly earnings.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 5.6 percent to $32.00 in pre-market trading after falling 2.26 percent on Thursday.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 5.6 percent to $9.30 in pre-market trading after reporting Q3 results.
    Aflac Incorporated (NYSE: AFL) rose 4.7 percent to $47.50 in pre-market trading.
    Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 4.2 percent to $2.24 in pre-market trading following Q1 earnings.
    Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) shares rose 3.7 percent to $11.00 in pre-market trading after the company reported Q1 earnings.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Shane Hupp]

    These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

    Get RXi Pharmaceuticals alerts:

    Intercellular Adhesion Molecule 1 Market Pipeline Review H1 Products in Clinical Stage, Methodology, therapeutic … (talkinvestor.com) Hypoxia Inducible Factor 1 Alpha Market Research Report H1: Drug Profile, Top Industry Intelligence and Therapeutic … (thestockanalysis.com) Connective Tissue Growth Factor Market Opportunities, Demands, Size, Share, Trends, Industry Sales Area and Its … (trueindustrynews.com) Global Connective Tissue Growth Factor Market 2018 – Manufacturing Analysis and Development Forecast 2025 (trueindustrynews.com) Zacks: Analysts Expect RXi Pharmaceuticals Corp (RXII) to Announce -$0.56 EPS (americanbankingnews.com)

    Shares of RXi Pharmaceuticals stock traded down $0.04 on Tuesday, hitting $1.92. The company had a trading volume of 27,600 shares, compared to its average volume of 258,173. The stock has a market capitalization of $8.21 million, a PE ratio of -0.46 and a beta of 1.20. RXi Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $7.70.

Hot Blue Chip Stocks To Own For 2019: Home Bancorp, Inc.(HBCP)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Home Bancorp (HBCP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Home Bancorp (HBCP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Beneficial Bancorp (NASDAQ: BNCL) and Home Bancorp (NASDAQ:HBCP) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Home Bancorp (HBCP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Media stories about Home Bancorp (NASDAQ:HBCP) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Home Bancorp earned a news impact score of 0.02 on Accern’s scale. Accern also gave press coverage about the bank an impact score of 47.6769620242767 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Hot Blue Chip Stocks To Own For 2019: Intuit Inc.(INTU)

Advisors’ Opinion:

  • [By Wayne Duggan]

    With bitcoin prices now at their highest levels since March at above $9,200, former Intuit Inc. (NASDAQ: INTU) and Paypal Holdings Inc (NASDAQ: PYPL) CEO Bill Harris wrote an op-ed piece for Recode in which he called bitcoin “the greatest scam in history.” Harris said cryptocurrencies are massive pump-and-dump schemes and fraud artists are taking advantage of cryptocurrency investors naivety and greed. He added that bitcoin has no intrinsic value, isn't an effective store of value and isn't accepted by the vast majority of businesses, making it virtually useless as a means of payment.

  • [By Daniel Sparks]

    With the big news that Intuit’s (NASDAQ:INTU) CEO and CTO are both stepping down at the end of the year, it’s easy to overlook the company’s fourth-quarter results. As the two executives get ready to head out the door, Intuit posted expectation-crushing numbers, including strong double-digit growth in both its small-business and self-employed segment and its consumer segment.

  • [By Daniel Sparks]

    Financial software specialist Intuit (NASDAQ:INTU) reports fiscal 2018 fourth-quarter results later this month.

    Expectations for the period are high. Setting the stage for an impressive finish to fiscal 2018, management gave its revenue guidance for the year a significant boost. And adding further pressure for a good fiscal fourth quarter is the fact that shares of Intuit have risen 54% in the past twelve months and 34% year to date, crushing the overall market’s returns.

  • [By Matt Krantz]

    Most brokerage firms will allow you to access papers online. Not only is that tidier, but it’s also more secure. Also, software like Quicken and online services like Personal Capital and Intuit’s (NASDAQ:INTU) Mint are much better than paper at pulling together all of your accounts, so you can see how much you have.

  • [By Lee Jackson]

    Intuit Inc. (NASDAQ: INTU) has been on a roll this year and hits all the metrics in the technology sector for accounting needs. The company is a provider of business and financial management solutions for small and medium-sized businesses, financial institutions, consumers and accounting professionals. Products and services include TurboTax, QuickBooks, Quicken, small business financial management and payroll processing, personal finance and tax preparation and filing and online banking services through its Digital Insight acquisition. Intuit also offers products on a software as a service (SaaS) platform across all its business divisions.

Leave a Reply

Your email address will not be published. Required fields are marked *